Regenerative medicine最新文献_第2页

ATMP clinical trials in the UK. 英国的 ATMP 临床试验。

IF 2.4 4区医学

Regenerative medicine Pub Date : 2024-11-01 Epub Date: 2024-11-16 DOI: 10.1080/17460751.2024.2427505

Rehma Chandaria, Philippa Rice, Daniel Baston, Finn Willingham, Jacqueline Barry

{"title":"ATMP clinical trials in the UK.","authors":"Rehma Chandaria, Philippa Rice, Daniel Baston, Finn Willingham, Jacqueline Barry","doi":"10.1080/17460751.2024.2427505","DOIUrl":"10.1080/17460751.2024.2427505","url":null,"abstract":"Aims: The UK advanced therapy medicinal product (ATMP) clinical trials database, produced annually by CGT Catapult, aims to assess the progress and state of the UK ATMP clinical development landscape. The aim of this article is to highlight key findings from the database and put them into context within the global landscape and various initiatives intended to attract ATMP developers to the UK.Method: A targeted search of GlobalData's clinical trial database was performed, followed by refinement so that only trials investigating products meeting ATMP definitions were included, and that each trial was only counted once in the analysis.Results: The 2023 data show that the number of ongoing ATMP clinical trials in the UK has remained approximately static, in contrast to a 10% reduction reported globally. Approximately 80% of these trials were commercially sponsored. Although most ATMP clinical trials are early phase, there is evidence indicating progression to later phase studies.Conclusion: The data indicate that the UK remains an attractive region for ATMP clinical trials. Factors including UK government investment in research, regulatory support offered by MHRA, and the Advanced Therapy Treatment Centre (ATTC) network of clinical sites, may contribute to the positive ecosystem available to developers of ATMPs.","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"541-548"},"PeriodicalIF":2.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statement of Retraction: The first Stem Cell-Based Tissue-Engineered Organ Replacement: Implications for Regenerative Medicine and Society. 撤回声明：首例基于干细胞的组织工程器官置换术：对再生医学和社会的影响》。

IF 2.4 4区医学

Regenerative medicine Pub Date : 2024-11-01 Epub Date: 2024-10-14 DOI: 10.1080/17576180.2024.2413823

引用次数: 0

Ultrasound-guided injection using leucocyte-rich platelet-rich plasma for treatment of meniscal injuries in a duathlete: a case report. 使用富含白细胞的血小板血浆在超声波引导下注射治疗一名双项全能运动员的半月板损伤：病例报告。

IF 2.4 4区医学

Regenerative medicine Pub Date : 2024-11-01 Epub Date: 2024-10-30 DOI: 10.1080/17460751.2024.2418705

Jeimylo C de Castro, Daniel Wang, Paschenelle Celis, Jeffrey Strakowski

引用次数: 0

Proliferation and differentiation of Wharton's jelly-derived mesenchymal stem cells on prgf-treated hydrogel scaffold. 沃顿果冻间充质干细胞在经 prgf 处理的水凝胶支架上的增殖和分化。

IF 2.4 4区医学

Regenerative medicine Pub Date : 2024-11-01 Epub Date: 2024-11-18 DOI: 10.1080/17460751.2024.2427513

Bahareh Pourjabbar, Forough Shams, Saeed Heidari Keshel, Esmaeil Biazar

{"title":"Proliferation and differentiation of Wharton's jelly-derived mesenchymal stem cells on prgf-treated hydrogel scaffold.","authors":"Bahareh Pourjabbar, Forough Shams, Saeed Heidari Keshel, Esmaeil Biazar","doi":"10.1080/17460751.2024.2427513","DOIUrl":"10.1080/17460751.2024.2427513","url":null,"abstract":"Background: To address the limitations of Cultivated Limbal Epithelial Transplantation (CLET) and the use of amniotic membrane (AM) in treating Limbal Stem Cell Deficiency (LSCD), we aimed to develop a Collagen/Silk Fibroin (Co/SF) scaffold enriched with Platelet-Rich Growth Factor (PRGF) to support the proliferation, maintenance, and differentiation of Wharton's jelly-derived mesenchymal stem cells (WJMSCs) into corneal epithelial cells (CECs).Method: Scaffolds loaded with PRGF were evaluated through release studies, cytotoxicity assays, and cell differentiation. The proliferation and differentiation of WJMSCs and Limbal Epithelial Stem Cells (LESCs) were investigated using MTT assays, real-time PCR and immunostaining.Results: The PRGF-loaded Co/SF scaffold significantly promoted the proliferation of both WJMSCs and LESCs in a concentration-dependent manner. Real-time PCR and immune staining revealed a significant increase in the expression of P63, ABCG2, and cytokeratin 3/12 markers in WJMSCs, a significant decrease in the expression of P63 and ABCG2, and a significant increase in the expression of cytokeratin 3/12 markers indicating successful differentiation into CECs.Conclusion: The WJMSC cultured on PRGF-enriched Co/SF scaffold demonstrates potential as a viable alternative to conventional CLET, offering a promising strategy for corneal tissue regeneration.","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"549-560"},"PeriodicalIF":2.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Extracellular vesicles for corneal regeneration: the new frontier. 用于角膜再生的细胞外囊泡：新领域。

IF 2.4 4区医学

Regenerative medicine Pub Date : 2024-11-01 Epub Date: 2024-10-18 DOI: 10.1080/17460751.2024.2412510

Keya Jafari, Ashkon Seyed-Safi, Sajjad Ahmad

引用次数: 0

Bone marrow aspirate concentrate for the treatment of fifth metatarsal head stress fracture: a case report. 骨髓抽吸浓缩物治疗第五跖骨头应力性骨折：病例报告。

IF 2.4 4区医学

Regenerative medicine Pub Date : 2024-11-01 Epub Date: 2024-11-26 DOI: 10.1080/17460751.2024.2422193

Hirotaka Nakagawa, Kristen Mitchell, Walter I Sussman

引用次数: 0

Industry updates from the field of stem cell research and regenerative medicine in July 2024.

IF 2.4 4区医学

Regenerative medicine Pub Date : 2024-11-01 Epub Date: 2024-10-14 DOI: 10.1080/17460751.2024.2402645

Dusko Ilic, Mirjana Liovic

引用次数: 0

Industry updates from the field of stem cell research and regenerative medicine in July 2024. 2024 年 7 月干细胞研究和再生医学领域的行业动态。

IF 2.4 4区医学

Regenerative medicine Pub Date : 2024-10-14 DOI: 10.1080/17460751.2024.2402645

Dusko Ilic, Mirjana Liovic

引用次数: 0

Regeneration of full thickness common extensor tendon tear after percutaneous microfragmented adipose graft. 经皮微碎脂肪移植后全厚总伸肌腱撕裂的再生。

IF 2.4 4区医学

Regenerative medicine Pub Date : 2024-10-10 DOI: 10.1080/17460751.2024.2393555

Imran J Siddiqui, Alyssa Ritner, Sanjay Mahadevan, Kyle J Dineen, Roosevelt Desronvilles

{"title":"Regeneration of full thickness common extensor tendon tear after percutaneous microfragmented adipose graft.","authors":"Imran J Siddiqui, Alyssa Ritner, Sanjay Mahadevan, Kyle J Dineen, Roosevelt Desronvilles","doi":"10.1080/17460751.2024.2393555","DOIUrl":"https://doi.org/10.1080/17460751.2024.2393555","url":null,"abstract":"Tennis elbow, also commonly known as lateral epicondylitis or common extensor tendinosis, is a common musculoskeletal injury in the adult population. Currently, the standard treatment regimen prescribed for this injury involves a combination of rest, physical therapy, bracing and anti-inflammatory medications. If refractory to these conservative measures, platelet-rich plasma has been shown effective. However, in the case of full thickness tears, surgery has remained the only treatment option until now. We present a case report of a 56-year-old man with a diagnosis of a left large full thickness tear and rupture with retraction of his common extensor tendon (CET) following a corticosteroid injection. The patient was treated with microfragmented adipose transfer. He was re-evaluated around 7 weeks and again at 15 weeks post-treatment and demonstrated ultrasound evidence of complete bridging and remodeling of his prior full thickness CET tear and resolution of retraction. This case presents a promising option for patients with full thickness CET tears who would like to refrain from or are unable to have surgery. Further research and possible randomized controlled trials are needed to further assess the full efficacy of microfragmented adipose transfer in the treatment of full thickness CET tears.","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"1-10"},"PeriodicalIF":2.4,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Towards stem cell therapies for hearing loss: awareness and perspectives of Australian audiologists and their patients. 听力损失的干细胞疗法：澳大利亚听力学家及其患者的认识和观点。

IF 2.4 4区医学

Regenerative medicine Pub Date : 2024-10-08 DOI: 10.1080/17460751.2024.2402650

Dysiphan Iem, Georgia Carney, Megan Munsie, Bryony A Nayagam

{"title":"Towards stem cell therapies for hearing loss: awareness and perspectives of Australian audiologists and their patients.","authors":"Dysiphan Iem, Georgia Carney, Megan Munsie, Bryony A Nayagam","doi":"10.1080/17460751.2024.2402650","DOIUrl":"10.1080/17460751.2024.2402650","url":null,"abstract":"Aim: Over the last two decades, numerous experimental studies have examined the feasibility of delivering stem cells into the cochlea to restore hearing. While these studies have spawned new cell therapy companies, there is little information on what patients understand or expect from these emerging therapies.Methods: This study sought to understand the awareness and perspectives of Australian audiologists and their adult patients toward stem cell therapies for treating hearing loss.Results: An anonymous survey indicated 91% of patients and 39% of audiologists were unaware of these therapies being developed. Thirty percent of audiologists reported being asked about stem cell therapies for hearing loss, but 70% were not confident answering patient queries about this and were unsure where to gather information. Primary concerns reported by patients were cost (45%) and safety of treatment (42%). Interestingly, 58% of patients were unsure of how this therapy would improve their hearing, yet 25% of these patients expected that their hearing would return to normal.Conclusion: There was strong support for development of educational materials for both patient and clinician. The increasingly important role of audiologists in providing patient counselling was reflected in overwhelming support (from both patient and clinician) for audiologists providing such information.","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"1-14"},"PeriodicalIF":2.4,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0